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Abstract 
 
 Arginine is an indispensable amino acid for the neonate. Significant quantities of both 
arginine and methionine are required for de novo creatine synthesis to satisfy whole body 
accretion requirements, even when creatine is provided in milk. Neonates that require 
intravenous feeding (parenteral nutrition, PN) are at risk for arginine deficiency because arginine 
is synthesized in the small intestine from dietary precursors; as such, arginine deficiency may 
limit creatine synthesis.  L-arginine:glycine amidinotransferase (AGAT) is the first enzyme, and 
the rate limiting step, involved in creatine biosynthesis and catalyzes the conversion of arginine 
and glycine to guanidinoacetic acid (GAA) in the kidney. GAA is then methylated by methionine 
in the liver to produce creatine via guanidinoacetate N-methyltransferase. Our objective was to 
determine whether a parenteral diet supplemented with GAA or creatine could spare arginine and 
methionine for protein synthesis and growth. Piglets (6-10 d old, N = 31) were parenterally fed 
for 5 days one of five diets: 1) low arginine and low methionine (base), 2) base plus GAA, 3) 
base plus creatine, 4) high arginine and high methionine (Arg&Met), or 5) high methionine and 
low arginine plus GAA (Met&GAA). On day 6 of the experiment, piglets underwent a 6-hour 
constant infusion of stable isotopes of arginine, GAA and creatine to measure fractional 
conversion of arginine to GAA and creatine. In addition, continuous infusions of phenylalanine 
and tyrosine isotopes were used to measure whole body protein kinetics. At the end of the 
experiment, the piglets were killed and AGAT activity and GAA and creatine concentrations 
were measured in tissues.  P values < 0.05 were considered statistically significant. In piglets fed 
the GAA and creatine diets, there was significantly lower kidney AGAT activity compared to the 
Arg&Met diet (P < 0.05), which indicates that GAA and creatine downregulated kidney AGAT 
and suggests that less arginine was used for GAA synthesis. Pancreatic AGAT activity was also 
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significantly lower in the creatine group compared to Arg&Met (P < 0.05). Whole body nitrogen 
balance did not differ significantly between groups, however, nitrogen retention was higher in 
the group fed GAA with excess methionine (Met&GAA), compared to GAA alone (P < 0.05) 
suggesting that methionine in the GAA group was directed towards GAA methylation rather than 
protein synthesis even when limited amounts of methionine were provided in the diet. This is 
consistent with the higher weight gain in the Met&GAA group compared to all other groups (P < 
0.05) except the Arg&Met. A greater amount of arginine was utilized for GAA synthesis in the 
Arg&Met group compared to the GAA, creatine, and Met&GAA groups (P < 0.05), which 
demonstrated that providing creatine or GAA in the diet spared arginine in those groups. Overall, 
supplemental GAA in parenterally fed piglets seemed to be effective at sparing arginine for 
growth, provided that methionine was supplemented in adequate amounts. GAA may be useful 
as a supplement to parenteral nutrition formulas to preserve arginine for growth by facilitating 
creatine synthesis. 
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Chapter 1: Literature Review 
1.1 Creatine 
Creatine has long been known to be an ergogenic sport supplement in high performance 
and intensity sports, such as football, weight lifting, and rugby (reviewed by Brosnan & Brosnan, 
2007). Creatine is a metabolic product of three amino acids, arginine, glycine, and methionine. 
Creatine can be either obtained from the diet (e.g. from meat, fish, or dairy) or by de novo 
synthesis from precursor amino acids. The interest in creatine has grown in recent years when it 
was discovered that it is involved in many diseases of the brain and muscle. Tissues that are 
major consumers of creatine are skeletal muscles, the heart, the spermatozoa, and the retina of 
the eye. The brain, brown adipose tissue, seminal vesicles, macrophages, intestines, and 
endothelial cells also utilize creatine but in intermediate amounts compared to the other tissues. 
Tissues that utilize very little amounts of creatine include the kidneys, spleen, liver, white 
adipose tissue, lungs, and red blood cells. Both creatine and creatine phosphate are slowly 
converted non-enzymatically to creatinine and excreted (reviewed by Wyss & Kaddurah-Daouk, 
2000).  According to Wyss and Kaddurah-Daouk (2000), it was estimated that a 70 kg male 
would have 120 g of total body creatine plus creatine phosphate. It was also estimated that 
~1.7% of the total creatine pool is lost daily as creatinine in the urine; therefore, this amounts to 
approximately 2 g of the total creatine pool that needs to be replenished each day. The 
consumption of “a typical western diet” (da Silva et al., 2009) provides ~50% of the body’s total 
creatine need for an adult. However, vegetarians and vegans acquire little to no creatine from 
their diet and so the vast majority of it has to be synthesized entirely from dietary precursors (da 
Silva et al., 2009; Brosnan & Brosnan, 2007).  
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1.1.1 Creatine/ phosphocreatine as an energy buffer 
Creatine and creatine phosphate act as an energy buffer, maintaining constant levels of 
ATP and ADP during high energy demand. 
Creatine + ATP                                Phosphocreatine + ADP 
This reaction is catalyzed by the enzyme creatine kinase (CK) (reviewed by Bessman & 
Carpenter, 1985). There are different isoenzymes of CK in the body, each of which are unique to 
specific tissues. The first CK isoenzyme is found in brain cells (B-CK), the second isoenzyme is 
expressed mostly in muscle cells (M-CK), and the third isoenzyme is specific only to the 
mitochondria (Mi-CK) (Wallimann et al., 1992). That there are various types of CK only 
emphasizes the importance of creatine in energy metabolism in the cell (Brosnan & Brosnan, 
2007). The CK-phosphocreatine system maintains energy in cells by preventing the 
uncontrollable increases of ADP concentrations, thus limiting the unnecessary loss of adenosine.  
Also, it maintains the availability of free protons needed for the regeneration of ATP. As a 
consequence, the CK-phosphocreatine system maintains constant energy levels during periods of 
high or fluctuating energy demand in various types of cells (Wallimann et al., 1992). 
1.1.2 Creatine as an energy shuttle 
Both creatine and phosphocreatine act as an energy shuttle, mobilizing high energy 
phosphates among different sites in the cell. These sites include the cytosol where energy is 
utilized and the mitochondria where energy is produced. It was proposed that what actually 
diffuses back and forth between these two sites is creatine and phosphocreatine, as opposed to 
ATP and ADP. This is likely due to the fact that ADP and ATP are heavier than creatine and 
phosphocreatine, and therefore, their mobilization might be more costly to the cell (Wallimann et 
al., 1992). During physical activity, creatine is released from the muscle fiber where it diffuses to 
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the mitochondria. After that, ATP is converted to ADP and phosphocreatine is produced where it 
is readily available to the cell (Bessman & Carpenter, 1985). 
1.2 Creatine biosynthesis 
Creatine synthesis is a simple process that occurs in two steps (Figure 1.1). In the first 
step of this reaction, an amidino group is transferred from arginine to glycine via the enzyme L- 
arginine:glycine amidinotransferase (AGAT) to produce guanidinoacetic acid (GAA) and 
ornithine in the kidney. GAA is then released into the circulation where it is taken up by the 
liver. In the second step of the reaction, GAA is methylated by S-adenosyl methionine (SAM) 
via the enzyme guanidinoacetate N-methyltransferase (GAMT) to produce creatine and S-
adenosylhomocysteine (SAH). Creatine is then released by the liver and distributed to tissues 
that utilize creatine (Wyss & Kaddurah-Daouk, 2000). 
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Figure 1.1 Creatine biosynthesis pathway 
L- arginine:glycine amidinotransferase (AGAT) catalyzes the reaction that transfers an amidino 
group from arginine to glycine to produce guanidinoacetic acid (GAA) and ornithine. GAA is 
then methylated by S-adenosyl-L-methionine (SAM) in the liver via guanidinoacetate N-
methyltransferase (GAMT) to produce creatine and S-adenosyl-L-homocysteine (SAH).  
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1.2.1 AGAT and the role of the kidney and pancreas in GAA synthesis 
In vertebrates, the highest expression of AGAT has been reported in the kidney, pancreas, 
and brain (da Silva et al., 2014). The kidney is suggested to be the most important contributor of 
GAA production, which is directed towards whole body creatine synthesis (Brosnan & Brosnan, 
2007). Nephrectomized rats displayed major reductions in GAA and creatine synthesis when 
compared to healthy rats, suggesting that the kidney is a key element in total body creatine 
synthesis (Levillain et al., 1995). The expression of renal AGAT is upregulated by growth and 
thyroxine hormones, and downregulated by creatine supplementation (Humm et al., 1997).  
Edison et al. (2007) examined GAA synthesis in the adult rat and human kidney. In the 
adult rat kidney, arginine was synthesized in the proximal convoluted tubule from citrulline, and 
then appeared to undergo a direct conversion to GAA. In that study, the kidney was the main 
contributor of GAA to whole body creatine synthesis; however, the kidney was directly affected 
by the dietary intake of creatine, which resulted in a reduction of the synthesis of GAA. Studies 
in humans have not been as clear. Edison et al. (2007) measured renal blood flow in healthy 
adults after the consumption of a normal meal (50% carbohydrates, 35% fat, and 15% protein). 
Results suggested that the human kidney may contribute only 20% of the total GAA needed for 
creatine synthesis, and that other organs may play a greater role in the synthesis of creatine such 
as the liver. The mechanism by which AGAT is regulated in other mammals clearly differs by 
species. In the neonatal piglet, however, AGAT activity was only detected in the kidney and 
pancreas (Brosnan et al., 2009). Although the pancreas displays 5-fold greater specific activity of 
AGAT compared to the kidney (Brosnan et al., 2009), the quantitative importance of the 
pancreas AGAT is not known, considering its small size relative to the kidney.  A study by da 
Silva et al., (2014) measured AGAT activity in the pancreas of rats fed supplemental creatine 
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and found that creatine supplementation lowered AGAT activity in both the pancreas and the 
kidney. Although there was a downregulation of AGAT activity in the pancreas, they found 
elevated GAA concentrations in that tissue when compared to controls. The researchers proposed 
that high plasma creatine concentrations might have a negative feedback mechanism on the GAA 
transporter, hence the accumulation of GAA in the tissue. However, unlike the kidney, the 
pancreas mRNA and protein expression of AGAT was not reduced by creatine supplementation, 
which suggests that the mechanism by which pancreatic AGAT is regulated is different than in 
the kidney. Further evidence is required to understand the role of this organ in total body creatine 
synthesis.  
1.2.2 GAMT and the role of the liver in creatine synthesis 
GAMT is the second enzyme in the creatine synthesis pathway, which catalyzes the 
methylation of GAA via S-adenosylmethionine (SAM) to produce creatine and S-
adenosylhomocysteine (SAH) (Brosnan et al., 2009). The liver is known to be the major 
producer of creatine in the body (Wyss & Kaddurah-Daouk, 2000). It is also the main site for the 
synthesis of SAM which is the major methyl donor in the body (reviewed by Bertolo & 
McBreairty, 2013). SAM is synthesized by the addition of an adenosine molecule to the amino 
acid methionine, which then methylates GAA to produce creatine and SAH. Unlike AGAT, 
creatine supplementation does not affect GAMT activity in piglets (Dinesh et al., 2018) or rats 
(da Silva et al., 2009). Some research has suggested that human livers might actually synthesize 
creatine entirely in the liver without relying on the kidney for GAA synthesis. In humans, it was 
found that AGAT mRNA is highly expressed in the liver. The fact that the urea cycle occurs in 
the liver may be suggestive that both the AGAT pathway and urea cycle occur hand in hand. 
Hence, the arginine in the liver has two outcomes: either it is converted to ornithine via arginase 
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I or converted to GAA and ornithine via AGAT. This process has been coined “the arginine 
bicycle” by researchers (reviewed by Brosnan & Brosnan, 2004). Evidence from rat studies has 
also suggested creatine is entirely synthesized in the liver, as immunofluorescent microscopy 
displayed very high levels of hepatic AGAT in the rat that were comparable with the kidney 
(McGuire et al., 1986). In contrast, a study by da Silva et al. (2009) tested this hypothesis in 
isolated rat hepatocytes, and found that there was no synthesis of creatine from its three amino 
acid precursors. They also found decreased uptake of GAA by the rat liver fed a creatine-
supplemented diet compared to control, as well as a decreased renal AGAT activity. These 
findings suggest that creatine synthesis in the rat is regulated at the renal level. In the piglet, 
evidence also suggests an interorgan synthesis that involves both the kidney and the liver. The 
highest GAMT activities were reported in the liver. Moderate to low amounts were detected in 
the pancreas, kidney, muscles, intestines, and brain (Brosnan et al., 2009). These findings 
suggest that the liver is the major contributor of creatine synthesis from renal GAA in the piglet. 
It is clear that creatine synthesis is an interorgan process that occurs via a renal-hepatic axis.  
 
1.3 Methionine requirement in neonates 
Methionine is an essential amino acid with many critical roles other than protein 
synthesis. Methionine serves as a methyl donor in the synthesis of phosphatidylcholine (PC), 
which is an important component in the structure of biological membranes. Methionine is also 
involved in the methylation of DNA, in addition to creatine synthesis. Methionine as a methyl 
donor acts as a precursor for over 200 transmethylation reactions through SAM (Petrossian & 
Clarke, 2011).  Methionine is also the amino acid precursor for cysteine, which is synthesized 
from homocysteine via transsulfuration (Bertolo & McBreairty, 2013). The amount of cysteine in 
the diet will alter the dietary methionine requirement. Piglets fed excess dietary cysteine required 
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less methionine in parenteral and enteral feeding trials (Shoveller et al., 2003b) compared to 
when fed cysteine-free diets (Shoveller et al., 2003a). Methionine is spared by cysteine, when 
less is directed towards the transsulfuration pathway (McBreairty et al., 2015). Therefore, more 
methionine would be available for protein synthesis and other methylation reactions. Methionine 
can be regenerated in the body through remethylation (via betaine from choline) or through 
methylneogenesis (via folate) (Bertolo & McBreairty, 2013). Therefore, the status of methionine 
is highly affected by the availability of the substrates involved in these two pathways. 
1.3.1 Transmethylation  
The production of SAM requires the adenosylation of methionine via the enzyme 
methionine adenosyltransferase (MAT) (Bertolo & McBreairty, 2013). The importance of SAM 
lies in the fact that it is the direct precursor for over 50 different methylation reactions. Hence, 
methionine deficiency may compromise a wide variety of important methylation reactions. The 
three most important SAM-dependent methyltransferases (quantitatively) in the body are 
GAMT, phosphatidylethanolamine methyltransferase (PEMT), and glycine N-methyltransferase 
(GNMT). PEMT pathway is responsible for approximately one-third of the total endogenous PC 
synthesis via SAM; the rest of PC is synthesized via the cytidine-5′-diphosphocholine (CDP-
choline) pathway. GNMT is involved in the regulation of SAM:SAH ratio which can be used as 
an indicator for the state of the transmethylation potential, where a lower ratio can lead to 
impairment of transmethylation reactions. It is also involved in the removal of excess 
methionine. Both GAMT and PEMT pathways consume the majority of the SAM-derived 
methyl groups (Williams & Schalinske, 2007). 
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1.3.2 Remethylation  
Once homocysteine is produced via transmethylation, it is either irreversibly converted to 
cysteine via transsulfuration or regenerated to methionine. The remethylation pathway represents 
the conversion of homocysteine to methionine via two different routes. In the first route, a 
methyl group is removed from folate and transferred to homocysteine via the enzyme methionine 
synthase with cyanocobalamin acting as a coenzyme, to regenerate methionine. The second route 
of remethylation occurs through the transfer of a methyl group from betaine through 
betaine:homocysteine methyltransferase to ultimately form  methionine. It has been found that 
methyl donors (choline, betaine, and folate) affect the remethylation rate which is very important 
during early development due to growth and rapidly expanding tissue pools (Bertolo & 
McBreairty, 2013). A study by Robinson et al. (2016) removed methyl donors from the diets of 
enterally-fed neonatal piglets, and reported lower whole body protein synthesis compared to 
piglets fed a diet sufficient in methyl donors. Therefore, choline, betaine, and folate are 
important contributors to maintaining the methionine cycle, and deficiencies in these three 
nutrients may compromise the availability of methionine or increase its requirement.  
1.4 Creatine in the neonate 
Creatine metabolism in the human neonate has not been studied extensively. However, 
there are multiple animal studies in which the importance and implications of this metabolite 
were examined. A study by Ellery et al. (2012) examined the supplementation of creatine in the 
diet of pregnant spiny mice in a model of asphyxia. Birth asphyxia can cause multiple 
complications in the neonate and is associated with a high mortality rate. Before birth, asphyxia 
was induced in the pregnant mice, and then the kidney of the mice pups was examined for signs 
of acute kidney injury. The creatine-supplemented group showed decreased expression of an 
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injury marker and normal kidney morphology compared to controls. These data suggest that 
creatine may have a protective effect in preventing some of the complications of birth asphyxia.  
In human infants, it was estimated that nearly 90% of the total body creatine acquired 
during growth is through de novo synthesis, and that breast milk marginally contributes to total 
body creatine pools (Edison et al., 2013). Data from piglets seem to support a similar trend. 
Brosnan and colleagues (2009) estimated that the sow-fed piglet acquires approximately 25% of 
creatine from sow milk, and 75% has be synthesized de novo. This estimation was calculated 
based on differences in tissue creatine concentrations at 4 versus 11 days of age in sow-fed 
piglets, and demonstrates the high need for creatine in growing animals undergoing rapid tissue 
expansion. It is clear that creatine synthesis is a major metabolic process in the growing neonate 
that might place significant burden on the precursor amino acids, but this has not been 
empirically determined. 
1.4.1 Creatine deficiency syndrome 
The importance of creatine in the neonate was not clearly identified until the 
characterization of several creatine deficiency syndromes. The deficiencies arise due to 
mutations in one of the two enzymes involved in the creatine synthesis pathway or in the creatine 
transporter (reviewed by Leuzzi, 2002). Each of these deficiencies can lead to the depletion of 
creatine stores in the body. GAMT deficiency is characterized by intellectual disability and 
severe epilepsy (Leuzzi, 2002). This is likely due to the high concentrations of GAA that 
accumulate in the brain and surrounding tissues. Treatment with a very high dose of creatine has 
been successful in reducing the epileptic seizure and other neurological developmental problems, 
in addition to replenishing creatine stores (Leuzzi, 2002). However, prevention of neurological 
consequences was only successful when intervention was administered early in life and before 
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the onset of symptoms (Leuzzi, 2002). AGAT deficiency results in no net synthesis of GAA in 
the body, hence, no creatine synthesis. AGAT deficiency shares some characteristics with 
GAMT deficiency, but AGAT deficiency has a much broader range of developmental and 
neurological symptoms. Similar to GAMT deficiency, pre-symptomatic intervention with 
creatine seemed to be successful. Of all of the inborn errors, creatine transporter deficiency is the 
most severe and the most difficult to treat. These patients have normal GAA blood profiles but 
abnormally high creatine concentrations. The lack of the creatine transporter means that creatine 
cannot be moved between cells (Leuzzi, 2002).  It is not known why creatine is essential for the 
normal function of the brain. Nonetheless, it has been hypothesized that creatine might act as a 
neuromodulator or have “neuroprotective effects” (Brosnan & Brosnan, 2007). Some of these 
protective effects of creatine might include the stimulation of the nerve cells to uptake glutamate 
near the synapse, as well as the maintenance of calcium homeostasis in the brain (Ferrante et al., 
2000). Rodent studies have demonstrated that under normal conditions, the creatine transporter 
SLC6A8 is expressed in the endothelial microcapillary cells of the blood brain barrier (BBB); 
however, there is no expression of the transporter in the astrocytes associated with the BBB 
(Reviewed by El‑Daher & Braissant, 2016).  This suggests that there is little access to 
peripherally-supplied creatine by the brain, and supports the idea that the brain relies on its own 
synthesis of creatine.  Both AGAT and GAMT expression have been demonstrated in various 
structures in the brain, but not within the same cell type.  It may be that GAA is transported 
within the brain from AGAT-expressing to GAMT-expressing cells, to complete the synthesis of 
creatine. In rodents, this process relied on the SLC6A8 creatine transporter for the movement of 
GAA (El‑Daher & Braissant, 2016).  If this is the case in humans, it would partially explain the 
severe pathology that occurs with creatine transporter deficiency, despite normal activities of 
		 12	
AGAT and GAMT.  (Reviewed by El‑Daher & Braissant, 2016). Most of this work has been 
conducted in mature rodent models.  In one study of neonatal piglets however, no AGAT activity 
was detected in the brain  (Brosnan et al., 2009), which may be a developmental or a species 
difference in the reliance on the periphery for the supply of creatine for the brain. It is clearly 
evident that creatine is essential in the normal development of the neonate.  
1.5 Arginine synthesis in the neonate  
 Arginine is considered an essential amino acid in neonates, and conditionally essential in 
adults during situations of stress, such as surgery (Brunton et al., 1999; Yu et al., 2001). It is 
involved not only in protein synthesis but in other non-protein roles as well. For example, 
arginine is a substrate for the synthesis of nitric oxide, which acts as a vasodilator and immune 
modulator. It is also necessary for the detoxification of ammonia through the urea cycle. 
Arginine is also involved in the synthesis of polyamines, which are important components in 
cellular expression during development and in cell protection during oxidative stress (reviewed 
by Flynn et al., 2002). It was speculated that both human and sow milk are deficient in arginine; 
therefore, the neonate must synthesize the majority of its requirement (Davis et al., 1994; 
Brunton et al., 1999). For example, the suckling piglet must synthesize approximately 60% of the 
whole body arginine requirement, with only 40% provided by the sow’s milk (Wu & Knabe, 
1994). Flynn et al., (2000) compared plasma arginine concentration of sow-fed piglets ages 1-3 
and 7-21 days old. They found that plasma arginine concentrations decreased dramatically 
between the ages of 3 to 14 days old. There was also a significant increase of plasma ammonia in 
the 7- and 14-day-old piglets compared to the 1-3-day-old piglets. This might suggest that sow 
milk is deficient in arginine and that the piglet cannot synthesize sufficient amounts to meet its 
own requirement. This view was further supported in a later study by Kim et al. (2004) who 
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measured the effects of supplementing arginine to milk-fed piglets, and found that the piglets’ 
growth was significantly increased compared to their non-supplemented controls.    
In neonates, de novo arginine synthesis occurs in the enterocytes of the small intestine. 
However, once the animal transitions from the neonatal stage towards weaning, the synthesis of 
arginine shifts to involve both the small intestine and the kidneys (Wu & Knabe, 1995). In older 
animals, the main route of de novo arginine synthesis is through L -∆1 -pyrroline-5-carboxylate 
synthase (P-5-C synthase) from glutamate which results in the synthesis of P-5-C. P-5-C is then 
converted to ornithine and subsequently citrulline which is released into the circulation and used 
to synthesize arginine in the kidney. In neonates, however, the activity of P-5-C synthase is low 
and located almost exclusively in the small intestines and thymus. Hence, there is negligible 
synthesis of citrulline or arginine from glutamate in the neonatal gut (reviewed by Bertolo & 
Burrin, 2008). In contrast, proline is the primary precursor for arginine synthesis in intestinal 
enterocytes (Bertolo et al., 2003). It is interesting to note that human and porcine milk have 
relatively low concentrations of preformed arginine, but quite high concentrations of proline 
relative to the needs of the neonate (Brunton et al., 1999).  
1.5.1 Arginine synthesis in the neonate and total parenteral nutrition  
Total parenteral nutrition (TPN) is used widely in the clinical care of newborns, and 
particularly preterm infants.  TPN involves the infusion of nutrients directly into the systemic 
circulation, by-passing first pass intestinal metabolism.  The amino acid profile of the early 
parenteral nutrition (PN) solutions used the composition of human milk as a template.  However, 
it became apparent quickly that the arginine concentration was too low to meet the metabolic 
needs of infants.  TPN-fed neonates showed symptoms of arginine deficiency as evidenced by 
high plasma ammonia concentrations (Batshaw et al., 1984; Thomas et al., 1982). In most cases, 
		 14	
the hyperammonemia was reversed by the IV administration of arginine (Batshaw et al., 1984). 
Neonatal piglets also showed a similar response to limited arginine in the diet. A study by 
Brunton et al. (1999) provided neonatal piglets with arginine-free TPN, which resulted in an 
extremely rapid rise of plasma ammonia concentrations over hours, despite adequate proline in 
the PN solution.  Piglets that were enterally-fed the same formulation did not develop 
hyperammonemia unless proline was also deleted; enteral diets devoid of arginine and proline 
exhibited a rapid rise in plasma ammonia, demonstrating the importance of first-pass intestinal 
metabolism of proline in maintaining arginine synthesis. The study also demonstrated that 
glutamate, which was included in the formulations, was not an adequate precursor for arginine 
synthesis when both arginine and proline were absent from the diet. The researchers concluded 
that the neonatal piglet cannot synthesize adequate arginine and proline to meet whole body 
requirements; therefore, both of these amino acids should be treated as co-indispensable. A 
subsequent study by Bertolo et al. (2003) found that almost 50% of arginine synthesis from 
proline occurred in the small intestine in 1-3-day-old intragastrically fed piglets; therefore, both 
arginine and proline are also considered co-indispensable in neonates. They also determined that 
both arginine and proline become essential in situations where the gut is compromised, such as 
during TPN feeding or intestinal disease. As a consequence, the requirement for arginine would 
be much higher when first-pass metabolism is bypassed (Bertolo et al., 2003). In human 
neonates, there is also evidence to support the use of proline as the main precursor for arginine 
synthesis in the small intestine. Tomlinson et al. (2011) quantified arginine synthesis in healthy 
preterm neonates fed breast milk or formula using multiple stable isotopes. They found that the 
majority of the arginine was synthesized from proline, and there was no net synthesis of arginine 
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from glutamate, confirming the findings in neonatal piglets and validating the piglet as a model 
for the infant with respect to arginine metabolism.  
During TPN, the gastrointestinal tract is bypassed, therefore lacking stimulation and 
inhibiting its natural function (Dinesh et al., 2014). As a consequence, the small intestine is more 
susceptible to inflammation and atrophy (Brunton et al., 2012; Dinesh et al., 2014).  A number of 
studies have demonstrated an association between arginine status and the risk for intestinal 
complications following premature birth.  In particular, low plasma arginine in premature 
neonates receiving TPN is associated with necrotizing enterocolitis (NEC) (Becker et al., 2000). 
NEC is a devastating condition caused by an infection of the intestine, characterized by 
inflammation, perforation, bleeding, and necrosis of a part or all of the gastrointestinal tract, and 
is associated with a high mortality rate (Azcarate-Peril et al., 2011; Llanos et al., 2002). The 
association between arginine status and the risk of developing NEC is complex, but may be 
influenced by the link between arginine and overall gut health.  Studies using TPN-fed piglets 
have clearly demonstrated gut atrophy which may be a cause or consequence of diminished 
arginine synthesis. A study by Dinesh and colleagues (2014) reported that TPN-fed neonatal 
piglets demonstrated gut atrophy that was partially avoided with the enteral supplementation of 
arginine alone. The IV supplementation of arginine, however, did not improve the morphology 
of the small intestine. Furthermore, Urschel et al. (2007) found that greater arginine synthesis 
occurred in TPN-fed piglets that were treated with hormone GLP-2 compared to a saline control. 
The authors attributed the arginine synthesis to enhanced small intestinal morphology induced by 
GLP-2; however, it was not sufficient enough to improve the whole body status of arginine. This 
emphasizes the importance of arginine in maintaining the structure and function of the gut.  
		 16	
It is clear that the use of TPN will compromise the synthesis of arginine in the gut, 
initially by the loss of first pass metabolism, and then further by intestinal atrophy and the 
reduction in metabolic mass of the gut.  Poor arginine status may lead to devastating outcomes 
such as NEC, but subtle deficiencies in arginine could contribute to slower growth and may 
impact de novo creatine synthesis. An important question is how arginine is partitioned between 
protein synthesis and growth and other fates such as creatine synthesis, particularly when its 
availability is limited by intestinal injury or parenteral feeding.  
1.6 Creatine synthesis and precursor amino acids  
1.6.1 Arginine  
The idea that creatine synthesis placed a burden on whole body arginine availability was 
initially proposed by Visek (1986). He argued that in adults, the equivalent of 70% of the dietary 
arginine intake is directed towards creatine synthesis, and that dietary intake alone is not 
satisfactory to meet the body’s requirement for other metabolic functions of arginine. This view 
was also put forward earlier by another researcher, Walser in 1983. Walser proposed that adults 
consuming a typical Western diet do not meet the requirement for arginine. However, it is now 
known that arginine is not an essential amino acid in healthy adults (Dioguardi, 2011). The 
previous two studies gave rise to the question whether young animals can synthesize enough 
arginine to meet their needs. The requirement of arginine for younger people would be even 
higher due to rapid growth and expanding tissues (Visek, 1986). Furthermore, this also raises the 
issue that dietary arginine might not be sufficient to support maximal growth in rapidly growing 
neonates.  
In neonatal piglets, it was estimated that the arginine required for creatine synthesis is 
equivalent to approximately 20% of the dietary intake of arginine (Brosnan et al., 2009).  It is 
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important to note that creatine synthesis generates ornithine, which could be used to regenerate 
arginine in the urea cycle. But it is not known whether the ornithine produced by AGAT in the 
kidney is converted back to arginine. Ornithine has the potential to be oxidized via ornithine 
aminotransferase (OAT) or converted to citrulline via carbamoyl phosphate synthetase-I (CPS-I) 
and then to arginine. However, the distribution of CPS-I enzyme is limited to the intestines and 
liver, and OAT has been found to be highly expressed in the kidney. Therefore, it is more likely 
that ornithine produced via renal AGAT is fully catabolized (reviewed by Brosnan et al., 2011). 
In situations where the small intestine is compromised, the risk of arginine deficiency increases, 
thus placing a greater burden on a dietary source of arginine. Therefore, in these situations, the 
status of arginine may be limiting growth and ultimately, creatine synthesis.  
1.6.2 Methionine  
SAM, as the major methyl donor, requires a constant supply of labile methyl groups 
through two routes: through the availability of labile methyl groups from dietary methionine, 
betaine, or choline or through a process called methylneogenesis (Brosnan et al., 2011). The 
latter route is dependent on folate; therefore, a deficiency of folate might compromise 
remethylation back to methionine (Bertolo & McBreairty, 2013). Clearly, the demand for 
methylation reactions is greatest in growing animals. Brosnan et al. (2009) have estimated that in 
growing sow-fed neonatal piglets, the equivalent of 35% of the dietary intake of methionine is 
utilized in creatine synthesis. Additionally, it was estimated that up to 77% of all of the labile 
methyl groups used in methylation reactions by the piglet are directed towards creatine synthesis. 
As such, creatine synthesis has the potential to be a burden on the availability of methionine, and 
in turn limit other important metabolic functions of methionine such as protein synthesis. 
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1.7 The concept of GAA and creatine sparing effects in animals 
The concept of amino acid sparing by the supplementation of GAA or creatine to the diet 
for growth was proposed very early in the literature. Fisher et al. (1956) compared three different 
diets to measure which one would result in greater growth in chicks. They supplemented a 25% 
casein diet with arginine, methionine, and glycine and compared it with a regular chick diet and a 
creatine-supplemented diet. They found that there was greater growth in chicks supplemented 
with arginine and glycine alone compared to the control diet, and that methionine had no effect 
on growth. However, creatine supplementation appeared to support an increased growth response 
when compared to control diet only. Furthermore, Austic & Nesheim (1972) measured arginine 
needs in chicks and found that most of the commercially available casein diets were deficient in 
arginine, and negatively affected growth. However, when the diets were supplemented with 
creatine, the chicks showed a positive growth response in spite of insufficient arginine. These 
two studies confirmed the importance of arginine for growth as well as the sparing effects of 
creatine on arginine availability. 
 There have been few studies in pigs that investigated the sparing effects of creatine. One 
study by Guzik et al. (2000) tested the effects of supplementing creatine to newly weaned pigs. 
They found that creatine supplementation did not affect growth or tissue creatine concentration 
regardless of the amount of creatine added to the diet.  The lack of response may be attributed to 
the inclusion of adequate amino acids in the diet to support optimal growth and creatine 
synthesis; thus there was no sparing benefit to additional creatine. Moreover, O’Quinn and 
colleagues (2000) measured the effects of creatine supplementation in growing finishing pigs. 
They found that creatine supplementation for 10 days did not affect the growth of these pigs. 
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Again, this might be attributed to the fact that their diets were not marginal in the precursor 
amino acids of creatine and consequently, no positive effect of creatine was observed.  
GAA has also been tested as a replacement for arginine in the agricultural industry. A 
recent study by Dilger et al. (2013) examined the supplementation of GAA to broiler chicks. 
GAA added to a diet marginal in arginine resulted in greater weight gain and growth than when 
GAA was supplemented to a diet adequate in arginine. This study was in agreement with a 
similar study by Almquist et al. (1941) where they tested the dietary supplementation of GAA in 
a typical chick diet. They found that GAA supplementation led to greater liver and muscle 
creatine concentrations compared to supplementing creatine alone. The sparing effects of GAA 
was also evaluated in swine. A recent study by McBreairty et al. (2015) found that 
supplementing GAA to a regular grower diet for weaned pigs increased tissue creatine 
concentrations compared to a diet supplemented with creatine, but with no growth effect. 
Nonetheless, it should be noted that excess amounts of GAA in the diet might actually lead to a 
depletion of methyl group supply, as more methionine is required to methylate GAA via hepatic 
GAMT (McBreairty et al., 2015).  Methionine balance should always be taken into consideration 
when supplementing GAA to ensure that other methylation reactions are not compromised. The 
long term effects of supplementing GAA in growing animals have not been investigated; 
however, studies in humans have shown that supplementing GAA in healthy men for a period of 
8 weeks resulted in increased brain creatine concentrations with no neurological side effects 
(Ostojic et al., 2017).  GAA is more stable than creatine in feed additives with much lower costs 
(Michiels et al., 2012), however, GAA was found to be slightly less soluble than creatine in 
aqueous solutions (Vraneš et al., 2017).  As the popularity of individual nutrient supplements 
grows, it remains an important question to understand how changes in one nutrient or metabolite, 
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such as GAA or creatine, might affect the use or requirement of others, particularly in rapidly 
growing neonates. 
1.8 Yucatan miniature piglets as a model for the human neonate 
Premature infants, depending on their gestational age at birth, are often born with 
immature organs and physiological functions, therefore complicating the treatment approaches 
that ensure the neonate’s survival. Because this vulnerable population of patients vary in birth 
conditions, there was a need to establish a neonatal animal model to investigate various 
interventions (Wykes et al., 1993). This animal model would allow researchers to understand 
how to efficiently support normal growth and development in this group while employing 
invasive procedures. As such, the neonatal piglet has become a well-established model for the 
human neonate (Wykes et al., 1993; Shulman, 1993). Neonatal piglets are considered an 
accelerated growth model for humans. Piglets grow more rapidly than humans, which enables 
researchers to detect physiological changes within shorter time periods, when different 
treatments are administered (Shulman, 1993). Both the neonatal piglet and human neonate show 
similar characteristics in terms of development, physiology, anatomy, and essential amino acid 
requirements (Wykes et al., 1993). For example, intestinal function and response to 
environmental stressors is very similar to the human infant, in addition to similar cardiovascular 
physiology (Shulman, 1993; Azcarate-Peril et al., 2011). Moreover, advantages of using 
miniature piglets as a model includes their smaller size, easy housing, as well as their docile 
temperament and acceptance of handling (Panepinto et al., 1978; Shulman, 1993). Both arginine 
(Brunton et al., 2003) and methionine (Shoveller et al., 2003a; Shoveller et al., 2003b) 
requirements have been studied in neonatal piglets. Hence, the neonatal piglet represents an 
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excellent comparative model for studying the metabolic pathways of both of these amino acids in 
the human neonate.  
1.8.1 Neonatal TPN piglet model 
The neonatal TPN piglet model was first established and validated by Wykes and 
colleagues in 1993. They compared 1-3-day-old TPN-fed piglets to sow-fed piglets. The 
formulation of TPN was based on the compositions of sow milk, published requirements 
(National Research Council, 1988), and knowledge of piglet gastrointestinal metabolism. The 
results of their study showed that the TPN-fed piglets had comparable growth rates to the sow-
fed group, and similar blood biochemistry profiles. Furthermore, the piglets were able to 
efficiently use the amino acids in the TPN formula as evidenced by a positive nitrogen balance. 
Additionally, this model is also considered clinically relevant, because the TPN formula was 
comparable to that used in clinical settings for infants. Therefore, the TPN-fed piglet model is an 
ideal model to demonstrate the effects of TPN manipulation, while ensuring the survival of the 
animal for the duration of the study.  
1.9 Whole body stable isotope kinetics 
Isotopes, whether stable or radioactive, have been used to measure the metabolic fate of 
different nutrients in the body. The use of radioisotopes is not favoured by researchers because in 
some cases, it is not considered ethical for use in human studies (Thompson et al., 1989). In 
animal studies, the use of both stable and radioisotopes is very popular with favour towards the 
latter due to lower analytical costs; however, in recent years, the use of mass spectrometry in 
research has grown exponentially, resulting in lower analytical costs. The advantages to stable 
isotopes are that they are generally safer to use, and also permit multiple investigations in one 
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animal. The use of isotopically labeled amino acids also allows for the quantification of the rate 
conversion of amino acids to other products in an in vivo state.  
 To measure the rate of conversion of amino acids, the flux of the amino acid and its 
products have to be measured through a representative body pool, most commonly plasma. We 
assume that the amino acid pool is well mixed (Welle, 1999; Wolfe, 1984). We also assume that 
the body “does not discriminate” (Clarke & Bier, 1982) between the tracer infused and the amino 
acid of interest; the fate of both the tracer and tracee has to be the same. Additionally, we assume 
that the tracer infused in the body pool does not re-enter the pool (Vella & Rizza, 2009). 
According to Figure 1.2, in a single amino acid pool model, at Time 0 the amount of amino acids 
entering the pool should be equal to the amount leaving the pool when the body is in equilibrium. 
Once the labeled amino acid appears intravenously at Time 1 (either from enteral or parenteral 
administration), the amount of label appearing in the pool is greater than the amount leaving the 
pool. After some time with continuous infusion of the labeled amino acid at Time 2, the amount 
of the label entering the pool would equal the amount of the label leaving the pool. Thus, we can 
say that the label has reached isotopic equilibrium or plateau; the ratio of tracer to tracee in the 
plasma is constant (Welle, 1999; Wolfe, 1984).  
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Figure 1.2 Single amino acid pool. (Inspired by Wolfe, 1984) 
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Isotopically labeled amino acids can also be used to measure protein dynamics in the 
body. The use of phenylalanine to measure its kinetics and protein turnover was not popular until 
the late 1980’s (reviewed by Matthews, 2007). As an essential amino acid, phenylalanine can 
only be obtained from the diet or from protein breakdown.  Phenylalanine has two fates in the 
body. It is either hydroxylated to tyrosine as the first step towards disposal of excess 
phenylalanine, or it is incorporated into proteins as phenylalanine or tyrosine; however, it cannot 
be stored (Wolfe, 1984; Welle, 1999). The greater the rate of oxidation of phenylalanine (as 
determined by hydroxylation into tyrosine), the lower the rate of incorporation of phenylalanine 
into protein; hence, less protein accretion would be expected (Clarke & Bier, 1982). Clarke and 
Bier (1982) were the first to establish that the hydroxylation of phenylalanine to tyrosine and the 
flux can both be measured using continuous infusion of L-[ring-2H5]-phenylalanine and L-[1-
13C]-tyrosine. Thompson et al. (1989) used the same principle, however, they modified it by 
priming the pools of both [2H4] tyrosine and [2H5] phenylalanine to achieve isotopic plateau more 
quickly, followed by continuous infusion of the isotopes. According to Thompson et al. (1989), 
the hydroxylation of phenylalanine to tyrosine can be quantified provided that tyrosine flux is 
measured using a distinguishable tracer, and the enrichment of tyrosine coming from a tracer of 
phenylalanine can also be measured (Short et al., 1999).  
The same principle of Thompson et al. (1989) can be applied to measure other amino 
acids and their respective products, such as the conversion of arginine to GAA and creatine. It 
would require the infusion of uniquely labeled isotopes of GAA and creatine to measure their 
fluxes and conversion rates.  
Because the conversion of phenylalanine to tyrosine can be used to estimate 
phenylalanine oxidation, one advantage of using the model described above is that it eliminates 
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the need to sample the label from breath (to determine amino acid oxidation) or urine and 
reduces the sampling to blood only (Thompson et al., 1989). One limitation of this model is the 
overestimation of whole body protein synthesis. It has been determined that the plasma 
enrichment of phenylalanine and tyrosine is almost 25% greater than the intracellular 
enrichment. The main hydroxylation site of phenylalanine is the liver; therefore, a better estimate 
of the enrichment would be provided by sampling at the site, or through the measurement of 
specific liver-derived plasma proteins such as Apo-B100. Moreover, measuring whole body 
protein synthesis may not provide enough detailed information about the protein status of the 
body and may not be sensitive enough to capture organ-specific differences in protein kinetics. 
Finally, some studies have reported that the use of specific phenylalanine tracers in metabolic 
studies might produce a kinetic isotope effect depending on the site of the label on the molecule. 
If the label is located on the aromatic group, it may alter the rate of the hydroxylation reaction. 
Reports in the literature varied between [ring-2H5] phenylalanine slowing phenylalanine 
hydroxylation or increasing the rate of reaction, when compared to phenylalanine labeled with 
[1- 13C] position, or with a 15N label and result in either an increase or decrease in the plasma 
enrichment (Matthews, 2007). A study done by Krempf et al. (1990) examined the fluxes of 
three different tracers of phenylalanine infused concurrently through the venous (IV) and 
intragastric (IG) routes in fasted subjects, L-[ring-2H5]-phenylalanine, L-[1- 13C]-phenylalanine, 
and L-[15N]-phenylalanine. They found that the IG fluxes were generally higher than the IV. In 
addition, the fluxes of the IV infused tracers did not differ regardless of label; however, L-[ring-
2H5]-phenylalanine had a significantly greater flux rate compared to the [1- 13C] and [15N] tracers 
when infused through IG. The researchers attributed this observation to possible “proton 
exchange” in the intestines. Another study done by Marchini et al. (1993) measured 
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phenylalanine hydroxylation in fasted and fed healthy men by the simultaneous primed infusion 
of L-[ring-2H5]-phenylalanine, L-[1- 13C]-phenylalanine, and L-[ring-2H4]-tyrosine. They found 
that L-[ring-2H5]-phenylalanine had a significantly decreased oxidation rate in comparison to L-
[1- 13C]-phenylalanine in both the fed and fasted state. They also argued that the use of L-[ring-
2H5]-phenylalanine might underestimate the in vivo hydroxylation of phenylalanine and 
recommended that a correction factor should be used to better approximate the hydroxylation 
rate. 
 
1.10 Research rationale 
Both arginine and methionine are indispensable amino acids in the neonate. Our 
laboratory has previously demonstrated that when arginine or methionine is limiting, creatine 
synthesis is impaired. Since a fraction of creatine and creatine phosphate are irreversibly 
converted to creatinine (~1.7%/day), there is a need to replace this lost pool (Wyss & Kaddurah-
Daouk, 2000). Furthermore, it was estimated that creatine synthesis consumes an equivalent of 
20% of the dietary intake of arginine (Brosnan et al., 2009) and as a consequence, with limited 
dietary supply, less arginine may be available for protein synthesis and ultimately, growth. In 
addition, TPN feeding inhibits the gut from producing arginine in the neonate, thus, increasing 
the risk of deficiency due to gut atrophy (Dinesh et al., 2014). Taken together, this information 
suggests that arginine deficiency may limit creatine synthesis. Finally, in a previous study from 
our laboratory, it was demonstrated that dietary arginine supplemented to TPN-fed piglets 
predicted tissue creatine concentrations (Gagnon, unpublished data). Therefore, using a TPN-fed 
piglet model, the current study addressed the question of how arginine is partitioned between 
protein and creatine synthesis when limited in the diet, and whether GAA or creatine effectively 
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spares arginine for growth. It was anticipated that arginine deficient diets will compromise 
creatine synthesis, and that supplementing GAA or creatine would spare arginine and/or 
methionine for protein synthesis and other metabolic functions.  
1.11 Hypothesis 
A parenteral diet supplemented with creatine or its precursor GAA will spare arginine 
and/or methionine for protein synthesis and growth in neonatal piglets. 
 
1.12 Specific objectives 
In this study, our objectives were:  
• to assess the capacity of the kidney and the pancreas to synthesize GAA via the enzyme 
AGAT  
• to measure the efficiency of dietary amino acid utilization as indicated by nitrogen 
retention 
•  to measure the concentrations of GAA and creatine in various tissues 
• to utilize stable isotopes to measure the partitioning of arginine into GAA and creatine 
under conditions of limited and excess arginine, and supplemental GAA and creatine  
• to measure whole body protein dynamics using tracers of phenylalanine and tyrosine 
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Chapter 2: Materials and Methods 
2.1 Animal Experimentation and Surgical Procedures 
Yucatan miniature piglets were used in this study (n= 31). All animal procedures were 
reviewed and approved by the Institutional Animal Care Committee at Memorial University of 
Newfoundland and conformed to the guidelines of the Canadian Council on Animal Care. 
Animals were obtained from a breeding colony at Memorial University of Newfoundland, St. 
John's, NL, Canada.  On the initial day of the study (day 0), piglets were transported from the 
breeding colony via Animal Care Services staff to the animal research facility (Biotechnology 
Building, Memorial University of Newfoundland). Piglets were weighed upon arrival and given 
an intramuscular injection of 22 mg.kg body weight-1  (BW) ketamine hydrochloride (Bimeda 
Canada, Cambridge, ON, Canada) and 0.5 mg.kg  BW-1  acepromazine (Vetoquinol, Quebec, 
Canada) mixed in one syringe to induce anesthesia. An intramuscular injection of buprenorphine 
hydrochloride (Temgesic, Reckitt Benckiser Healthcare, Berkshire, UK) at a dose of 0.03 mg.kg 
BW-1 was also administered intramuscularly for analgesic effects. Once the pre-anesthetic had 
taken effect, the piglets were cleaned with Prepodyne solution (West Pentone, Quebec, Canada), 
70% isopropanol, and Prepodyne scrub (West Pentone, Quebec, Canada).  The pigs were then 
placed on a surgical table, and general anesthesia was induced using 1.5% isoflurane anesthesia 
(Abbott Laboratories Inc., Markham, ON, Canada) mixed with oxygen (1.5 ml.min-1). Under 
sterile conditions, a catheter (described below) was implanted in the left external jugular vein 
and advanced to the superior vena cava. Another catheter was implanted in the left femoral vein 
and advanced to the inferior vena cava. The jugular catheter was used for intravenous diet 
infusion and femoral catheter was used for blood sampling. After the surgery was completed, 0.5 
mL of the antibiotic Borgal (trimethoprim 40 mg.ml-1 and sulfadoxine 200 mg.ml-1; Intervet 
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Canada Ltd, Kirkland, QC, Canada) diluted to 10 mL with normal saline was injected in both of 
the catheters to prevent infection, along with 5 mL of heparinized saline to prevent the formation 
of clots in the catheters. Antibacterial Hibitane ointment (chlorhexidine acetate 1% w/w 
veterinary ointment; Wyeth, Kirkland, QC, Canada) was administered to the incision sites to 
prevent infection and aid in recovery. Piglets were then moved to a housing room where they 
remained for the rest of the study. The temperature of the room was kept at 28°C with a 12-hour 
light and 12-hour dark cycle. The piglets were placed in metabolic cages. A tether and swivel 
system (Lomir Biomedical, Montreal, Canada) was used that attached to a jacket which was 
fitted securely on the piglet. This enabled the safe infusion of the intravenous treatments while 
allowing the piglets to move freely inside the cage. Heat lamps attached to the cages provided 
supplemental heat.  The piglets were housed individually, but were able to see and socialize with 
each other.  
The study protocol is presented in Figure 2.1. For the first two days of study, the piglets 
were provided with a nutritionally complete parenteral adaptation diet to aid in recovery 
(Appendix I). This adaptation diet was infused at 50% of the target rate (13.5 ml.kg BW-1 .h-1) on 
the day of surgery. The following morning, the rate was increased to 75% of target, and 
advanced to 100% by the evening of day 1. The IV diets were delivered as a constant infusion 
via pressure-sensitive, hospital-grade peristaltic pumps that were accurate to 1 mL per hour 
(Baxter Healthcare Corporation, Deerfield, USA).  The piglets were monitored daily for signs of 
pain or infection. Buprenorphine hydrochloride (0.015 mg.kg BW-1) was administered in the 
evening post-surgery as well as the next morning. At the end of day 2, piglets were randomized 
to one of the five parenteral experimental diets (Table 2.1). Blood samples were taken daily (0.7 
ml) to measure plasma ammonia using an ammonia assay kit (Sigma-Aldrich, Oakville, Canada). 
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The piglets were weighed daily, and the rate of diet infused was adjusted accordingly. On day 6 
of the experiment, a 6-hour constant infusion of stable isotopes was performed to determine the 
kinetics of amino acids, creatine and GAA, as well as whole body protein dynamics. On day 7, a 
6-hour constant infusion of L-[methyl-3H]-methionine was performed followed by necropsy with 
tissue collection. All tissues collected were freeze-clamped using liquid nitrogen, and stored at -
80˚C for later analysis.  The results of the radioisotope infusion study on day 7 are not presented 
in this thesis and constitute the MSc thesis work of Scott Bray (S.B.).  All of the work involved 
in carrying out the procedures and animal care described above were shared equally by A.A. and 
S.B. 
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Figure 2.1 The timeline of the experiment. 
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2.2 Catheters 
Silastic catheters were assembled in our laboratory.  Jugular catheters were made of 
silastic tubing (i.d. 0.76 mm, o.d. 1.65 mm) attached to a lever lock cannula (Becton Dickinson 
& Co., New Jersey, USA). For the femoral catheters, the tubing (i.d. 0.63 mm, o.d. 1.19 mm) 
was attached to a blunt cannula (Becton Dickinson & Co., New Jersey, USA). All catheters were 
sterilized using an ethylene oxide gas sterilizer (Anderson Products, North Carolina, USA).  
2.3 Parenteral Diets 
All diets provided 1.1 MJ non protein energy.kg BW-1 and the equivalent of ~15.5 g.kg 
BW-1.day-1 delivered as crystalline amino acids (Table 2.1).  
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Table 2.1 The amino acid composition of the experimental parenteral diet 
Amino Acid Base GAA Creatine Arg&Met Met&GAA 
  g.kg BW-1.day-1  
Alanine 2.59 2.37 2.37 0.00 2.13 
Arginine 0.550 0.550 0.550 1.800 0.550 
Aspartate  0.942 0.942 0.942 0.628 0.942 
Cysteine 0.224 0.224 0.224 0.224 0.224 
Glutamate 1.63 1.63 1.63 1.63 1.63 
Glycine 0.357 0.357 0.357 0.357 0.357 
Histidine 0.479 0.479 0.479 0.479 0.479 
Isoleucine 0.718 0.718 0.718 0.718 0.718 
Leucine 1.62 1.62 1.62 1.62 1.62 
Lysine-HCl 1.29 1.29 1.29 1.29 1.29 
Methionine 0.100 0.100 0.100 0.500 0.500 
Phenylalanine 0.610 0.610 0.610 0.610 0.610 
Proline 1.29 1.29 1.29 1.29 1.29 
Serine 0.868 0.868 0.868 0.868 0.868 
Taurine 0.075 0.075 0.075 0.075 0.075 
Tryptophan 0.329 0.329 0.329 0.329 0.329 
Tyrosine 0.117 0.117 0.117 0.117 0.117 
Valine 0.823 0.823 0.823 0.823 0.823 
Threonine 0.823 0.823 0.823 0.823 0.823 
Creatine monohydrate 0.00 0.00 0.118 0.00 0.00 
GAA 0.00 0.093 0.00 0.00 0.093 
Glycyl-L-tyrosine dihydrate* 0.385 0.385 0.385 0.385 0.385 
Total amino acids 15.8 15.7 15.7 14.7 15.8 
* Glycyl-L-tyrosine provided 0.293 g.kg BW-1.day-1  of tyrosine and 0.121 g.kg BW-1.day-1 of glycine.  	 
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2.3.1 Adaptation parenteral nutrition 
The adaptation PN composition was modified from the work of Wykes et al. (1993) 
(Appendix I). The diet was prepared in the laboratory using crystalline L-amino acids 
(Ajinomoto North America Inc., North Carolina, USA; Evonik Industries AG, Hanau-Wolfgang, 
Germany; Sigma, St. Louis, MO, USA; USB Corporations, Cleveland, OH, USA; Merck 
Schuchardt OHG, Hohenbrunn, Germany). The amino acids were weighed individually, mixed 
well, and then dissolved slowly in 4 L of pyrogen-free water, heated to 55-60°C, and maintained 
under a blanket of nitrogen gas to prevent the oxidation of amino acids. Once the amino acids 
were completely dissolved, D-glucose and major minerals (Appendix III) were added. More 
pyrogen-free water was added to the solution to bring it up to the final volume.  The diet solution 
was sterilized by working in a laminar airflow cabinet while cold filtering through a 0.22 µm 
filter (AcroPak, Pall Corporation, Switzerland) into sterile IV bags (Baxter Corporation, 
Mississauga, ON, Canada). The diet-filled bags were stored at 4˚C away from light, until needed.  
2.3.2 Trace elements 
The trace elements were estimated based on the work of Wykes et al. (1993) (Appendix 
II). The individual trace elements were weighed out and mixed with pyrogen-free water. The 
mixture was then filtered through a sterile 0.22 µm syringe filter (Millipore Ireland Ltd., Ireland) 
into a sterile IV bag (Baxter Corporation, Mississauga, ON, Canada). The trace elements solution 
was kept refrigerated until needed.  
2.3.3 Multivitamins  
Injectable vitamins were a commercial product (Infuvite Pediatric-Multiple Vitamins, 
Baxter Health Corporation, Illinois, USA).  The product was provided as two separate vials that 
required mixing just prior to adding to the PN diet (Table 2.1). Just prior to using the diet-filled 
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IV bags, 3 mL of vitamin preparation, 3 mL of trace elements, 1 mL of injectable iron (IPCO, 
Saskatoon, Canada; 3 mg/kg BW), and 145 mL of 20% Intralipid emulsion (Fresenius Kabi, 
Uppsala, Sweden) were added to 750 mL of prepared diet and inverted repeatedly to ensure 
proper mixing.  
2.3.4 Experimental parenteral diets 
The experimental diets were prepared by using the same procedures as described in 2.3.1 
for the adaptation diet.  The composition of the experimental diets was based on the adaptation 
diet, with modifications (Table 2.1). To ensure that all diets were isonitrogenous, the 
concentrations of alanine and aspartate were adjusted accordingly (Table 2.1).  
 
Base diet (Base): The base diet was marginal in both arginine (0.55 g.kg BW-1.day-1) and 
methionine (0.10 g.kg BW-1.day-1) and was considered as the negative control. Based on the 
work by Shoveller et al. (2003b), the methionine requirement in PN-fed piglets was 0.18 g.kg 
BW-1.day-1 (when cysteine was included in excess). Therefore, this diet provided ~55% of the 
methionine requirement for PN-fed piglets. The arginine concentration chosen for this study was 
previously demonstrated to be low enough to impair protein synthesis in piglets without causing 
other adverse outcomes such a hyperammonemia or death (Brunton et al., 2003); as such, this 
should allow us to detect differences among treatment groups and the negative control, when 
creatine or its precursors are added to the diet.  
Base + GAA diet (GAA): The purpose of this diet was to test if a dietary source of GAA could 
spare arginine for protein synthesis. The piglets in this diet group received 0.093 g.kg BW-1.day-
1.  If converted entirely to creatine, this amount would supply enough creatine to meet the 
neonatal piglets’ daily accretion rate (Brosnan et al., 2009); therefore, we could determine 
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whether less arginine is converted to GAA when it is supplied in the diet, making it more 
available for protein synthesis.  
Base + creatine diet (Creatine): The purpose of this diet was to test if creatine supplementation 
would spare both arginine and methionine for growth and protein synthesis. This treatment 
allowed us to determine whether less arginine is directed towards GAA synthesis and whether 
methionine is spared from GAA methylation, because preformed creatine was supplied in the 
diet. The piglets in this group received 0.118 g creatine.kg BW-1.day-1, which was estimated to 
meet 100% of the daily creatine accretion rate in neonatal piglets (Brosnan et al., 2009).  
Adequate arginine and methionine diet (Arg&Met): This diet served as a positive control and 
provided a direct comparison to the Base diet. The arginine concentration in this diet provided 
1.8 g.kg BW-1.day-1, and was chosen based on a previous study that predicted greater than 1.2 
g.kg BW-1.day-1 is required to satisfy the whole body metabolic needs of arginine (Brunton et al., 
2003). The methionine concentration in this diet supplied 0.5 g.kg BW-1.day-1 which was almost 
triple the requirement of methionine determined for PN-fed piglets and double that for enterally 
fed piglets (Shoveller et al., 2003b).  
Low arginine + GAA + adequate methionine diet (Met&GAA): The composition of this diet 
allowed for direct comparison to the Base + GAA diet. Excess methionine was supplied to 
support maximal conversion of GAA to creatine. We also predicted that excess GAA could 
contribute to methionine deficiency, because large amounts of methionine would be required to 
methylate GAA via hepatic GAMT. Therefore, this diet group acted as a direct comparison to the 
Base + GAA diet to elucidate whether methionine deficiency contributed to impaired protein 
synthesis.  
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2.4 Analytical methods 
2.4.1 In vitro AGAT activity 
The AGAT activity in both the kidney and the pancreatic tissues was measured in vitro. 
The method was adapted from the method by Van Pilsum et al. (1970). In this reaction, the 
ornithine produced in the presence of arginine and glycine reacts with ninhydrin to form a 
yellow-orange color. Sodium fluoride (NaF) is used to inhibit ornithine production by arginase in 
the reaction, so the ornithine produced can be used to estimate the activity of AGAT. Frozen 
pulverized tissue was diluted with 50 mM potassium phosphate buffer (pH 7.4) (1:5, w/v).  The 
samples were then homogenized for 25 s at 50% speed. Next, the samples were diluted to 1:20 
(v/v) with the same buffer, resulting in a 1% homogenate. Four more additional buffers were 
prepared using the same potassium phosphate buffer (20 mL each) as follows: -Arg/-Gly (0.0285 
g NaF), -Arg/+Gly (0.069 g Gly and 0.0285 g NaF), +Arg/-Gly (0.1045 g arginine and 0.0285 g 
NaF), and +Arg/+Gly (0.1045 g Arg, 0.069 g Gly, and 0.0285 g NaF). 0.5 mL of samples were 
added to 0.5 mL of each of the buffers and incubated in a shaking water bath at 37˚C for 60 min. 
After 60 min, the reactions were stopped with 1.5 mL of 0.6 M perchloric acid. Next, the 
samples were centrifuged at 4˚C using a speed of 10621 g for 5 minutes. The samples were then 
placed on ice. A ninhydrin solution (6 g ninhydrin mixed in 100 mL 1-propanol) was prepared 
and 1.5 mL was added to each sample and to a series of ornithine standards. The samples were 
mixed well and transferred to a 92˚C water bath for 25 min, and then left to cool. The resulting 
colour was read using a microplate spectrophotometer (BioTeK, Vermont, USA) at a wave 
length of 505 nm. A calibration curve was constructed to calculate the unknown concentration of 
ornithine.  
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The concentration of ornithine in each sample was calculated based on the following 
equation: 
1. ∆OD due to AGAT = ∆OD (+Arg/+Gly) – [∆OD (+Arg/-Gly) + ∆OD (-Arg/+Gly) - ∆OD 
(-Arg/-Gly)] 
2. nmol ornithine in the unknown sample = [(∆OD due to AGAT – b) / m] 
3. nmol ornithine. min-1. g kidney-1 = nmol ornithine in unknown sample / (60 minutes x g 
tissue in assay medium) 
Where OD is the optical density, b is the y-intercept and m is the slope from the standard curve 
equation. 
2.4.2 Nitrogen balance 
Starting on day 4 of the experiment, the diet bag was weighed. ~5 mL of 18.4 M 
sulphuric acid was added to the clean urine collecting flask, and the flask was weighed. After 24 
h, the diet pump was stopped and the diet bag was weighed again. The urine flask was also 
weighed and a urine sample was collected and stored in -20˚C for later analysis. The procedure 
was repeated for two subsequent days, to provide total of 3 urine samples, each a sample from 24 
h pooled urine. Stool was not collected because PN-treated animals stopped defecating by day 4.  
Accurate records of quantity of diet infusion were maintained and were used to calculate the 
actual nitrogen intake.  
The urine samples were analyzed using a LECO system (FP-528) (LECO Corp., 
Michigan, USA). Frozen urine samples were thawed on ice. 1 mL of the thawed sample was 
neutralized using 6 M NaOH.  The neutralized samples were centrifuged (Eppendorf centrifuge 
5804R) at 10621 g for 5 minutes to remove any solids. Six 50 mg samples of Na2EDTA•2H2O 
were used as a standard. 100 µL of urine was weighed into a Leco tin foil cone and sealed. The 
		 39	
samples were then placed onto the loading head of the instrument and purged of all atmospheric 
gases. The samples were then dropped into an 850˚C furnace, which combusts the samples in the 
presence of pure oxygen. This combustion yields in CO2, H2O, NOx, and N2. All of these 
products were then passed through a furnace filter and a thermoelectric cooler where they were 
collected in a ballast apparatus, then homogenized via passive mixing. A 3 cc aliquot of the 
mixed gases was passed through hot copper for the removal of oxygen and for the conversion of 
NOx to N2. After that, the aliquot is passed through Lecosorb and Anhydrone for the removal of 
CO2 and water. The reaction results in nitrogen that was measured by thermal conductivity cells 
(Leco, 2008).  
2.4.2.1 Nitrogen balance calculations 
Nitrogen Excreted (g.kg BW-1.day-1) = [urine output (g.kg BW-1.day-1) x urine nitrogen 
concentration       (mg.g-1) ] / 1000 
Nitrogen Balance (g.kg BW-1.day-1) = nitrogen intake (g.kg BW-1.day-1) –  
nitrogen excreted (g.kg BW-1.day-1)  
% Nitrogen Retention = [nitrogen balance (g.kg BW-1.day-1) / nitrogen intake (g.kg BW-1.day-1)] x 
100 
 
2.4.3 GAA and creatine tissue concentrations 
The analysis of tissue GAA and creatine concentrations was based on the method by 
Buchberger and Ferdig (2004). This method was applied to kidney, pancreas, and brain tissues. 2 
mL of 1 M perchloric acid was added to 0.5 g of frozen pulverized tissues. The tissue was then 
homogenized at 50% speed for 25 seconds. After that, the homogenate was centrifuged at 4˚C 
using a speed of 17131 g for 20 minutes.  The supernatant was then transferred to new tubes and 
neutralized (pH 6.5 – 7) using 50% K2CO3 and 20% KOH. The solution was centrifuged again at 
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4˚C and 10621 g for 10 minutes. 400 µL was aliquoted for derivatization with ninhydrin. 300 µL 
of 1.5 M KOH was added to 400 µL of sample followed by 150 µL of 0.9% ninhydrin. The 
sample was mixed well and left to incubate at room temperature for 15 minutes. After that, 5% 
ascorbic acid followed by 5 M phosphoric acid was added to the sample then incubated in a 90˚C 
water bath for 30 minutes. Next, the samples were left to cool down and then filtered through a 
0.45 µm PTFE syringe filter (Canadian Life Science, Peterborough, Canada). The filtered 
samples were injected into a YMC-Pack Pro C18 column (150 X 4.6 mm I.D, 3 µm; YMC 
America, Inc, Allentown, PA, USA). The derivatized GAA and creatine were separated via 
reverse-phase HPLC using a dual buffer system (Mobile phase A: 50 mM formic acid and 
mobile phase B: 100% methanol). Peaks were detected by Waters 474 scanning fluorescence 
detector at 470 nm emission and 390 nm excitation. The run time for each sample was 37 
minutes with a flow rate of 0.5 ml.minute-1. A standard curve was used for quantification of the 
peak areas which was determined using Empower Software (Waters, version 3, 2010, Waters 
Corporation, Woburn, MA, USA). 
2.4.4 In vivo stable isotope kinetics 
2.4.4.1 Isotope preparation and procedures 
On the morning of day 6, piglets were weighed and 0.7 mL blood sample was drawn into 
a K2EDTA vacutainer tube (4 ml; 13 x 75 mm), and centrifuged for 5 minutes at 1300 g (VWR 
Clinical 200, Hermle Labortechnik, Wehingen, Germany). A priming infusion was given as a bolus 
into the jugular catheter and contained the following isotopes: L-arginine-13C6-HCl, 
guanidineacetic acid-2,2-D2, creatine-D3-H2O (methyl D3), L-[ring-D5]-phenylalanine, L-[ring-
D4]-tyrosine, L-[ring-3,5-D2]-tyrosine. Immediately following, a constant infusion was initiated 
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through the same catheter.  The constant infusion contained all of the isotopes, except for L-[ring-
3,5-D2]-tyrosine. Isotope prime and constant infusion doses are presented in Table 2.2. The test 
diets were continued during the isotopes infusion experiment, and the amino acid compositions of 
the test diets were adjusted to accommodate the contribution of the isotopically labeled amino 
acids. The constant infusion continued for 6 hours, and blood samples were drawn from the 
femoral catheter every half hour (Figure 2.2). All blood samples were centrifuged immediately 
and plasma was collected in Eppendorf tubes and stored at -80 ˚C for later analysis. The plasma 
samples were analyzed at the Analytical Facility for Bioactive Molecules (AFBM) of the Centre 
for the Study of Complex Childhood Diseases (CSCCD) at the Hospital for Sick Children, 
Toronto, Ontario.  
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Table 2.2 The compositions of the prime and constant doses for stable isotope infusion 
Isotope Prime  
mg.kg BW-1 
Constant 
mg.kg BW-1.h-1 
Products/Outcome 
L-arginine-13C6-HCl 3.64 6.07 
 
Arginine flux, GAAM+1, CreatineM+1 
Guanidineacetic-2,2-D2 0.61 1.02 
 
GAAM+2 flux, CreatineM+2, rate of 
GAA synthesis from arginine 
Creatine-D3-H2O 
(Methyl D3) 
1.5 1.5 
 
CreatineM+3 flux , rate of synthesis 
from arginine and GAA 
L-[ring-D5]-
Phenylalanine 
1.09 
 
3.4 
 
TyrM+4, Phe flux, Phe hydroxylation to 
Tyr (surrogate for Phe oxidation) 
 L-[ring-D4]-tyrosine 0.51 NA Tyr M+4 (priming the product pool) 
L-[ring-3,5-D2]-
tyrosine 
0.5 1.65 
 
TyrM+2 flux 
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Figure 2.2 Stable isotope infusion and blood sampling protocol 
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2.4.4.2 Sample preparation 
Plasma samples were thawed on ice and 200 µL of methanol was added to 25 µL plasma 
and centrifuged at 4˚C and 17949 g (Eppendorf Canada, Mississauga, ON, Canada). The 
supernatant was transferred to glass tubes, covered with parafilm, frozen in liquid nitrogen then 
kept at -80˚C for 20 minutes. The samples were then placed in a freeze dryer overnight (Thermo 
Savant, Canada). The next day, the samples were removed and stored at -80˚C until shipped on 
dry ice to the facility in Toronto. When samples arrived, they were reconstituted with 1 mL of 
10/90 water/acetonitrile 5 mM ammonium formate at a pH of 3.2.  
LC-MS-MS Analysis 
Sample analysis was performed with an injection volume of 5 µL on a Sciex QTrap 5500 
mass spectrometer (Framingham, Massachusetts, USA) and Agilent 1290 HPLC system (Agilent 
Technologies: Santa Clara, California, USA). Chromatography was run at a flow rate of 500 
µl.minute-1 on a Kinetex HILIC column (4.6 x 50 mm, 2.6 µm) (Phenomenex, Torrance, 
California, USA) with a gradient starting at 5% A (90/10 water/acetonitrile 5 mM ammonium 
formate pH 3.2), and 95% B (10/90 water/acetonitrile 5 mM ammonium formate pH 3.2) ramped 
to 100% A at 5 minutes and returning to initial conditions at 6 minutes for re-equilibration and a 
total run time of 10 minutes. 
Acquisition was performed in positive mode ESI with a source temperature of 600°C and 
an ion spray voltage setting of 5300. MRM mass transitions (m/z) were as follows: arginine 
175.1-70.0, arginine (M+6) 181.1-74.0, creatine 132.1-90.0, creatine (M+1) 133.1-90.0, creatine 
(M+2) 134.1-92.0, creatine (M+3) 135.1-93.0, guanidinoacetate 118.1-76.0, guanidinoacetate 
(M+1) 119.1-76.0, guanidinoacetate (M+2) 120.1-78.0, phenylalanine 166.1-120.0, 
phenylalanine (M+5) 171.1-125.0, tyrosine(a) 182.1-136.0, tyrosine(b) 182.1-91.0, tyrosine 
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(M+1) 183.1-91.0, tyrosine (M+2) 184.1-138.0, tyrosine (M+4) 186.1-140.0. Peak integration 
and data analysis were performed using Analyst 1.6.3 software spectrometer (Sciex, 
Framingham, Massachusetts, USA). Area ratios were calculated by plotting peak areas of the 
labelled mass transition/peak areas of the unlabeled mass transition for each analyte. 
 
 
2.4.4.3 Calculations 
Isotope enrichment 
Enrichment (atom percent excess, APE) was calculated using the following equation (Wilson et 
al., 2000):  
APE = [(Rs – Rb) / (1 + Rs) – Rb] x 100 
Where Rs is tracer:tracee in enriched sample; Rb is the tracer:tracee in natural abundance  
 
Amino acid flux 
The whole body amino acid flux was needed to calculate molar conversions. The flux was 
calculated using the following equation (Tomlinson et al., 2011): 
(Flux) (µmol. kg BW-1 .h-1)  = I x [(Ei/Ep)-1] 
Where I is the isotope infusion rate; Ei is the enrichment in the infusate; Ep is the enrichment in 
plasma.  
Precursor to product conversion rate 
Precursor to product conversion rate was calculated based on the following equation (Tomlinson 
et al., 2011):		
Qprecursor>product (µmol. kg BW-1 .h-1) = (Eproduct/ Eprecursor) x Qproduct 
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Where Q is the flux; E is the enrichment. 
Whole body protein dynamics 
Whole body protein dynamics was calculated based on the following equations (de Betue et al., 
2017): 
a. protein synthesis:  
Whole Body Protein Synthesis (µmol. kg BW-1 .h-1)  = QPhe – (Phe to Tyr conversion rate)  
b. protein breakdown: 
Whole Body Protein Breakdown (µmol. kg BW-1 .h-1)  = QPhe – Phe infusion rate 
c. protein accretion: 
Whole Body Protein Accretion (µmol. kg BW-1 .h-1)  = Protein Synthesis – Protein Breakdown 
2.5 Statistical analysis 
All resulted were calculated using one-way ANOVA followed by Tukey’s multiple 
comparison test via GraphPad Prism 7 (GraphPad Softwear Inc., CA, USA). P values less than 
0.05 were considered statistically significant.  
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Chapter 3: Results 
The study was divided into two sets of outcomes. The first set of outcomes was to 
investigate the whole body protein dynamics and the whole body partitioning of arginine into 
GAA and creatine using a stable isotope technique, which is included in this thesis. The second 
set of outcomes was to describe tissue-specific methionine metabolism, and comprised the MSc 
thesis of S.B. (not reported here). 
In total, 31 piglets were used for this study, which allowed a sample size of 6 piglets per 
treatment group. All piglets survived for the duration of the study.  However, one of the piglets 
in the GAA group developed gastric ulcers that were discovered during necropsy. Therefore, one 
extra piglet was added to the GAA group to ensure that the outcomes of the study had complete 
data sets.  After the analyses were completed, the affected piglet’s results were within the range 
of its treatment group, so the data were included resulting in n=7 for GAA.  
 
3.1 Weight gain 
The mean body weights of the piglets among treatment groups were not significantly 
different at the start of the study or at necropsy. All piglets gained weight during the study (Fig. 
3.1). The greatest weight gain was exhibited by the Met&GAA group which was significantly 
greater than piglets on the arginine and methionine deficient treatments (Base, GAA, and 
Creatine), with the Arg&Met group intermediate.  
 
 
 
 
		 48	
 
 
 
 
 
 
Figure 3.1: Daily weight gain across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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3.2 Nitrogen balance 
Whole body nitrogen balance did not differ significantly between groups when expressed as 
g.kg-1.day-1 (Figure 3.2). However, when expressed as percent of nitrogen retained (Figure 3.3), 
significant differences were observed.  
 
 
 
 
 
Figure 3.2 Nitrogen balance across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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There was significantly greater percent nitrogen retention in the Met&GAA compared to 
the GAA group only. The supplementation of creatine or excess arginine and methionine did not 
affect percent nitrogen retention.  
 
 
 
 
Figure 3.3 Percent nitrogen retention across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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3.3 In vitro AGAT activity 
AGAT activity in the kidney (Figure 3.4) was significantly greater in the Arg&Met group 
compared to the GAA and Creatine groups. The supplementation of creatine or its precursor 
GAA with low arginine appeared to negatively downregulate AGAT activity in the kidney 
compared to when arginine or methionine is supplemented in excess.  
 
 
 
 
Figure 3.4 AGAT activity in kidney across diet treatments 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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AGAT activity in the pancreas (Figure 3.5) followed a similar trend as in the kidney 
(Figure 3.4); however, only the creatine group was significantly lower than the Arg&Met group, 
with no other differences. It appeared that supplementing creatine also negatively downregulated 
AGAT in the pancreas compared to when arginine and methionine were supplemented in excess.  
 
 
 
 
 
Figure 3.5 AGAT activity in pancreas across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
 
 
 
 
 
 
 
 
 
Base 	GAA Crea*ne Arg&Met Met&GAA
0
500
1000
1500
Pa
nc
re
as
	A
GA
T	
ac
*v
ity
(n
m
ol
.m
in
-¹ .
g-
¹ 	*
ss
ue
)
Pancreas AGAT 
ab ab
a
b ab
		 53	
3.4 GAA and creatine tissue concentrations 
3.4.1 Tissue GAA concentrations 
Brain GAA concentrations were not different among treatment diets (Figure 3.6).  
 
 
 
 
 
 
Figure 3.6 Brain GAA concentration across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparison test; different letters indicate statistical differences 
(P< 0.05). 
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Kidney GAA concentration was highest in the Arg&Met group, and was significantly 
greater than all other groups, including the groups that were provided with supplemental GAA 
(Figure 3.7). 
 
 
 
 
Figure 3.7 Kidney GAA concentration across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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Similar to the results in the kidney, the pancreas GAA concentration was highest in the 
Arg&Met group and was significantly greater than all other groups (Figure 3.8).  
 
 
 
 
 
 
Figure 3.8 Pancreas GAA concentrations across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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3.4.2 Tissue creatine concentrations  
Similar to the GAA concentration in the brain, the brain creatine concentrations also did 
not differ in response to treatment (Figure 3.9).  
 
 
 
 
 
Figure 3.9 Brain creatine concentrations across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparison test; different letters indicate statistical differences 
(P< 0.05). 
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There was significantly greater kidney creatine concentration in the Met&GAA group 
compared to the Arg&Met group, with no other differences detected (Figure 3.10). 
 
 
 
 
Figure 3.10 Kidney creatine concentrations across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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There were no differences in pancreas creatine concentration across all diet treatments 
(Figure 3.11).  
 
 
Figure 3.11 Pancreas creatine concentrations across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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3.5 In vivo stable isotope kinetics 
3.5.1 Isotope enrichment 
All of the infusion concentrations of stable isotopes of amino acids, GAA and creatine 
were successful at producing measurable enrichments in their respective plasma pools as well as 
their respective products. Measurable enrichment was not detected in two piglets in the base 
group (for creatine M+1) and in the Met&GAA group (for creatine M+3) (Table 3.1). To 
determine steady state, plasma tracer:tracee ratios were plotted over time and plateaus were 
visually identified and confirmed by a non-significant linear regression. The mean of these 
plateau values was used to calculate the enrichment of each metabolite isotope. 
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Table 3.1 Isotope enrichment by diet treatment 
 
Isotope 
Base GAA Creatine 
 
Arg&Met 
 
Met&GAA 
Atom percent excess 
Arg (M+6) 8.21±0.730ab 8.50±0.480b 7.66±0.538a 8.09±0.316ab 8.68±0.304b 
 
GAA (M+1) 4.85±1.14ab 3.96±1.28a 5.84±1.25b 
 6.29±0.663b 
 
5.06±0.885ab 
 
Creatine (M+1) 0.983±0.190a 
 
0.628±0.304a 
 
0.867±0.160a 
 
2.17±0.352b 
 
0.935±0.239a 
GAA (M+2) 25.5±4.47a 27.2±5.66a 37.8±2.28b 29.9±6.70ab 30.7±6.10ab 
 
Creatine (M+2) 7.84±1.47ac 
 
6.62±2.55a 
 
9.21±1.05ac 
 
13.6±1.46b 
 
9.72±1.45c 
 
Creatine (M+3) 16.5±2.71a 
 
15.0±3.07a 
 
16.1±3.12ab 21.8±2.38b 
 
16.3±3.13a 
 
Phe (M+5) 7.87±0.463 
 
7.87±0.654 
 
8.00±0.384 
 
7.71±0.604 
 
7.85±0.517 
 
Tyr (M+4) 0.793±0.199b 
 
0.716±0.210ab 
 
0.995±0.232b 
 
0.470±0.098a 
 
0.704±0.180ab 
 
Tyr (M+2) 4.13±0.306 
 
4.08±0.530 3.99±0.246 4.23±0.279 4.25±0.249 
 
 
Values are means ± SD; n=6 per group, except for Base (n=5), Met&GAA (n=5), and GAA (n=7). 
Data were analyzed using a one-way ANOVA followed by a Tukey’s multiple comparisons test; different 
letters indicate statistical differences (P< 0.05). 
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3.5.2 Amino acid flux 
Whole body turnover or flux of the amino acids, GAA and creatine was calculated by 
using the steady state enrichment of the isotope in the plasma and infusate, as well as the rate of 
the isotope infusion. These fluxes were then used to measure the whole body rate of the 
conversion of the precursor to the product.  
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Table 3.2 The fluxes of amino acids by diet treatment 
 
Amino Acid 
Base GAA Creatine 
 
Arg&Met 
 
Met&GAA 
umol.kg BW-1.h-1 
Arg  320±43.3ab 303±19.1a 339±25.8b 319±13.5ab 295±11.2a 
GAA  25.8±5.46 24.55±9.16 14.2±1.98 
 
21.9±9.91 
 
20.4±6.76 
 
Creatine  51.4±10.2ab 
 
58.0±12.1b 
 
49.9±10.7ab 
 
35.7±5.14a 
 
52.1±10.2ab 
Phe  234±14.6 
 
235±21.3 
 
230±11.8 
 
240±19.7 
 
236±16.8 
 
Tyr  210±16.8 
 
215±27.7 218±14.3 205±15.3 204±11.9 
 
 
Values are means ± SD; n=6 per group, except for Met&GAA (n=5), and GAA (n=7). 
Data were analyzed using a one-way ANOVA followed by a Tukey’s multiple comparisons test.; 
different letters indicate statistical differences (P< 0.05). 
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3.5.3 Precursor to product conversion rate 
The whole body conversion rate of arginine to GAA was greatest when piglets were 
provided with high arginine and methionine (Arg&Met) in the PN diet (Figure 3.12).  The data 
followed a similar pattern to that observed for kidney AGAT activity (Figure 3.4). When 
compared to excess arginine and methionine, the supplementation of GAA, creatine, or 
GAA&Met resulted in less arginine being converted to GAA.  The data in Figure 3.13 
demonstrate the conversion of arginine to creatine; similar to the production of GAA, 
supplementation with GAA, creatine, or GAA&Met also resulted in less arginine conversion to 
creatine.  
 
 
 
Figure 3.12 Arg (M+6) to GAA (M+1) whole body conversion rate across diet treatment. 
 
 Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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Figure 3.13 Arg (M+6) to creatine (M+1) whole body conversion rate across diet 
treatments. 
Values are means ± SD; n=6 per group, except for Base (n=5), Met&GAA (n=5), and GAA (n=7). 
Data were analyzed using a one-way ANOVA followed by a Tukey’s multiple comparisons test; different 
letters indicate statistical differences (P< 0.05). 
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There were no differences in the conversion rate of GAA to creatine regardless of the 
label. The amount of GAA converted to creatine that was derived from the arginine tracer did not 
differ among groups (Figure 3.14). In addition, there were no differences observed in the rate of 
creatine production from the infused GAA tracer (Figure 3.15).  
 
 
 
 
 
Figure 3.14 GAA (M+1) to creatine (M+1) whole body conversion rate across diet 
treatments. 
Values are means ± SD; n=6 per group, except for Base (n=5), Met&GAA (n=5), and GAA (n=7). 
Data were analyzed using a one-way ANOVA followed by a Tukey’s multiple comparisons test; different 
letters indicate statistical differences (P< 0.05). 
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Figure 3.15 GAA (M+2) to creatine (M+2) whole body conversion rate across diet 
treatments. 
Values are means ± SD; n=6 per group, except for Met&GAA (n=5), and GAA (n=7). 
Data were analyzed using a one-way ANOVA followed by a Tukey’s multiple comparisons test; different 
letters indicate statistical differences (P< 0.05). 
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The conversion of phenylalanine to tyrosine was measured to estimate the oxidation of 
phenylalanine, in order to calculate whole body protein synthesis (Figure 3.16).  Greater 
hydroxylation of phenylalanine to tyrosine was measured in the creatine-supplemented group 
compared to Arg&Met group only. There was no effect of supplementing GAA or GAA and 
excess methionine on the rate of phenylalanine hydroxylation.  
 
 
 
 
 
Figure 3.16 Phe (M+5) to Tyr (M+4) whole body conversion rate across diet treatments.  
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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3.5.4 Whole body protein dynamics 
Whole body protein synthesis and breakdown did not differ by treatment group (Figures 
3.17 and 3.18); however, protein accretion was significantly greater in the Arg&Met group 
compared to the creatine-supplemented group only (Figure 3.19).  
 
 
 
 
Figure 3.17 Whole body protein synthesis rate across diet treatments. 
 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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Figure 3.18 Whole body protein breakdown rate across diet treatments. 
 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
 
 
 
Figure 3.19 Whole body protein accretion rate across diet treatments. 
Values are means ± SD; n=6 per group, except for GAA (n=7). Data were analyzed using a one-way 
ANOVA followed by a Tukey’s multiple comparisons test; different letters indicate statistical differences 
(P< 0.05). 
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Chapter 4: Discussion 
Creatine biosynthesis is an important metabolic pathway in the neonatal piglet (Brosnan 
et al., 2009). In spite of creatine intake from milk, the suckling neonatal piglet must still 
synthesize 75% of its creatine requirement from amino acid precursors (Brosnan et al., 2009). 
Creatine biosynthesis consumes appreciable amounts of the precursor amino acids, equivalent to 
approximately 20% and 35% of the dietary intake of arginine and methionine, respectively, even 
when considering the creatine provided in milk (Brosnan et al., 2009). Neonates can synthesize 
arginine and the main site of endogenous arginine synthesis is the enterocytes of the small 
intestine (Brunton et al., 1999). It was estimated that approximately 50% of the neonate’s 
arginine requirement is synthesized in the small intestine from proline (Bertolo et al., 2003). 
Therefore, if intestinal metabolism is compromised, such as with atrophy resulting from TPN 
feeding, arginine synthesis will be limited and will place the animal at risk of deficiency (Dinesh 
et al., 2014). In this situation, greater dietary arginine is necessary to satisfy all of the metabolic 
roles for arginine, including creatine synthesis. The supplementation of GAA, or its product 
creatine, to spare the precursor amino acids has been reported in the literature. The 
supplementation of GAA was studied in broiler chicks (Dilger et al., 2013), and weaned pigs 
(McBreairty et al., 2015) and was found to increase tissue creatine concentrations compared to 
when creatine was given as the supplement. In a different study, creatine supplementation was 
tested in newly weaned pigs; however, it did not affect piglets’ growth regardless of the amount 
added to the diet (Guzik et al., 2000). Another study tested creatine supplementation in growing 
finishing pigs and also found no positive effect on growth (O’Quinn et al., 2000). However, both 
of these studies provided sufficient amounts of the precursor amino acids, likely satisfying the 
requirement for creatine synthesis; as a consequence, no additional sparing benefit of 
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supplementing creatine was observed. We measured the effects of GAA or creatine 
supplementation when arginine and methionine were marginal in the diet, as well as diets where 
both arginine and methionine were presumably in excess. We also aimed to determine the effect 
of GAA supplementation on the availability of methionine; therefore, we added an additional 
diet group that was supplemented with GAA with methionine in excess. The objectives of this 
study were to assess the piglet’s response to supplementation of varying amounts of dietary 
arginine, methionine, creatine, or GAA during TPN. We did this by quantifying the molar 
conversions of arginine into GAA, creatine, and whole body protein dynamics, by measuring 
tissue AGAT activity, quantifying the distribution of creatine and GAA in various tissues, and 
measuring nitrogen retention in order to determine the efficiency of dietary amino acid 
utilization. 
4.1 The effect of GAA or creatine supplementation on whole body arginine kinetics 
and whole body protein dynamics 
Theoretically, if dietary arginine and methionine are limited, then sparing these amino 
acids by the supplementation of creatine or its precursor GAA would lead to increased protein 
synthesis and growth. In this study, we observed no beneficial growth effect with the 
supplementation of GAA (alone) or creatine (Figure 3.1). Similar to McBreairty et al. (2015), 
GAA or creatine supplementation to weaned pigs did not affect growth compared to controls. 
Only when methionine was supplied in excess with GAA did we observe an advantage in weight 
gain, which demonstrated that dietary methionine was limiting growth. Indeed, all of the groups 
on low methionine PN grew more slowly than the group given GAA and methionine in excess.  
Limited methionine availability will limit protein synthesis; however, weight gain is not 
necessarily indicative of lean mass accretion. Nitrogen balance is a better marker of whole body 
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protein gain.  In this study, the pattern in the nitrogen balance data (Figure 3.2) tended to parallel 
the weight gain data (Figure 3.1), but the only significant difference occurred between the piglets 
provided with GAA and those given GAA with high methionine when nitrogen balance was 
expressed as nitrogen retention (Figure 3.3). Taken together, these data demonstrate that 
methionine was limiting and that supplemental methionine enhanced whole body protein 
retention and growth. 
GAA requires methionine for its conversion to creatine via GAMT, which is responsible 
for the methylation of GAA via SAM, to produce SAH and creatine in the liver (Wyss & 
Kaddurah-Daouk, 2000). Our group recently showed that when methionine is limited, creatine 
synthesis is prioritized over other methylation reactions (McBreairty et al., 2013). In addition, 
GAMT activity is not regulated by creatine; hence, creatine synthesis in the liver is always 
proportional to the amount of GAA available, provided sufficient methionine is available 
(McBreairty et al., 2013). Indeed, methionine deficiency can be induced by experimentally 
depleting methyl groups through the IV infusion of GAA. McBreairty and colleagues (2013) 
measured the effect of infusing GAA into 15-18 day-old suckling piglets that were either of a 
normal weight or intrauterine growth-restricted. The infusion of GAA in both groups induced a 
very high rate of methylation of GAA to creatine, at the expense of PC and protein synthesis. In 
our GAA plus methionine supplemented piglets, excess methionine appeared to satisfy the GAA 
methylation needs for the conversion to creatine, as well as the need for protein synthesis as 
demonstrated by greater nitrogen retention (Figure 3.3).  
Another method of assessing efficiency of amino acid utilization was the measurement of 
whole body protein synthesis using isotope tracers.  We infused stable isotopes of phenylalanine 
and tyrosine to measure the oxidation of phenylalanine via its conversion to tyrosine (the first 
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step in phenylalanine oxidation), and the non-oxidative disposal of phenylalanine, which 
represents whole body protein synthesis. It should be noted that dietary tyrosine was supplied in 
excess to avoid the need for tyrosine synthesis from phenylalanine. In contrast to our hypothesis, 
we found significantly greater hydroxylation of phenylalanine to tyrosine in the creatine group 
(Figure 3.16), indicating less incorporation of phenylalanine into proteins. Theoretically, we 
expected that the supplementation of creatine or GAA to a diet marginal in arginine would 
alleviate the need for arginine use for creatine synthesis, and shift arginine towards protein 
synthesis. It is interesting that we did not find this, as it is in contrast to the evidence from the 
arginine isotope tracer results. The arginine tracer indicated that less arginine was partitioned 
toward GAA synthesis when creatine or GAA was included in the diet (Figure 3.12).  So 
arginine sparing was occurring, but not to enhance whole protein synthesis. The spared arginine 
may have been directed towards other metabolic pathways, or it may have enhanced organ-
specific protein synthesis, such as in the liver, but was not detectable at the level of whole body 
kinetics.   
Only when arginine and methionine were supplied in excess did they enhance the rate of 
whole body protein accretion (Figure 3.19), but only compared to creatine which had the lowest 
protein accretion. However, neither protein accretion nor nitrogen balance was different between 
the deficient Base group and the adequate methionine and arginine group, which raises the 
question of whether the arginine provided in the adequate group was in fact high enough to 
satisfy all of the metabolic requirements for arginine. Brunton et al. (2003) determined that 
(creatine-free) PN-fed piglets require >1.2 g.kg BW-1.day-1 of dietary arginine to satisfy its 
protein synthesis needs in the presence of an atrophied gut. Based on that, we determined that 
our adequate arginine group would be fed 1.8 g.kg BW-1.day-1 to meet or perhaps exceed 
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arginine requirements. Therefore, we should expect that that amount of arginine in the diet would 
meet the requirements for both creatine and protein synthesis, and that a supply of 0.55 g.kg BW-
1.day-1 of arginine (the limiting groups) should impair protein synthesis, without adversely 
harming the piglets by the consequential hyperammonemia (Brunton et al., 2003). However, our 
limited arginine groups only negatively affected protein accretion when creatine was 
supplemented, which is contradictory to what we expected. It is also possible that the low 
arginine group was not deficient leading to similar protein accretion, although this is unlikely 
given that PN arginine levels of 0.45 g.kg BW-1.day-1 are likely to lead to life-threatening 
hyperammonemia (Brunton et al., 2003). Because methionine was also deficient and 
supplemented with arginine, it is also notable that methionine deficiency did not lead to lower 
protein accretion. Using the same rationale, it is possible that the level of methionine used was 
not deficient in this Yucatan miniature pig model, perhaps because this strain of pigs is slower 
growing than domestic piglets used in previous PN methionine requirement studies (Shoveller, et 
al., 2003a; Shoveller, et al., 2003b). 
  
4.2 The effect of GAA or creatine supplementation on AGAT activity and tissue 
distributions of GAA and creatine 
In neonatal piglets, AGAT has been found to be highly expressed in the pancreas and 
kidney (Brosnan et al., 2009). The expression of renal AGAT is upregulated by growth and 
thyroxine hormones, and downregulated by creatine supplementation (Humm et al., 1997). 
Evidence in the literature is highly suggestive of the kidney being the major contributor to 
creatine synthesis through the production of renal GAA and subsequent methylation via hepatic 
GAMT (Brosnan et al., 2009). Dinesh and colleagues (2018) found renal AGAT downregulation 
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when neonatal piglets were supplemented with creatine in PN diets for two weeks compared to 
controls. We report the same result for creatine supplementation, and further, GAA in the PN 
also caused a down-regulation of AGAT activity in the kidney (Figure 3.4). Similarly, Edison et 
al. (2007) found a reduction of AGAT activity and GAA production in rat kidney when creatine 
was supplemented in the diet. It is interesting to note that the activity of AGAT in the pancreas 
(Figure 3.5) was also affected by the provision of creatine to the piglets, but GAA 
supplementation did not produce the same down-regulation as measured in the kidney. da Silva 
et al. (2014) also found a downregulation of AGAT activity of rat pancreas when supplemented 
with creatine. It is possible that the pancreas responds differently to GAA supplementation than 
the kidney. It has been identified that both human and pig AGAT share at least 94% of the amino 
acid sequence (Humm et al., 1994); in addition, Gross et al. (1986) found that humans express 
different isoforms of AGAT. Therefore, it is possible that the AGAT isoforms expressed in the 
pig kidney and pancreas are different, which may explain our reported differences in the AGAT 
responses to GAA in these tissues.  
The use of isotope tracers of amino acids is one of the popular methods to quantify the 
conversion or oxidation of each amino acid; the technique also allows for in vivo measurement of 
protein dynamics (Matthews, 2007). Although costly to analyze, the use of stable isotopes allows 
multiple tracers to be infused simultaneously to measure the fate of different metabolites at the 
same time. In this study, the method was very valuable, as it facilitated whole body kinetics 
measurements without the need to kill the piglets. The piglets underwent the stable isotope study 
on one day, and then underwent an additional radio-isotope tracer study the following day (data 
reported in the thesis of S.B.). From the stable isotope tracer data, we found that plasma arginine 
to GAA conversion rates (Figure 3.12) were supported by the enzyme activity data (Figure 3.4), 
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sharing a similar pattern. As predicted by the AGAT activity, the inclusion of creatine or GAA 
led to a lower conversion of arginine to GAA (Figure 3.12). Therefore, the addition of GAA or 
creatine spared arginine from GAA synthesis. The conversion of plasma arginine to creatine 
(Figure 3.13) includes the methylation step via GAMT. The provision of creatine or GAA also 
led to a lower conversion of arginine to creatine. However, the presence of GAA or creatine in 
the diet did not affect how much GAA was being converted to creatine (Figures 3.14 & 3.15), 
which was not different among treatments. While the provision of creatine or GAA down-
regulated AGAT, no apparent changes in GAMT activity occurred, supporting the concept that 
AGAT is the rate limiting step in creatine synthesis.  
Furthermore, the supplementation of excess arginine and methionine caused greater GAA 
retention in the kidney (Figure 3.7) which suggests that more arginine was utilized for the 
synthesis of GAA via renal AGAT. These data also suggest that supplementing creatine alone or 
GAA plus methionine may have spared arginine from GAA synthesis in the kidney. The 
supplementation of GAA appeared to enhance the tissue concentration of creatine in the kidney, 
but only when methionine was provided in excess to facilitate GAA methylation (Figure 3.10).  
Interestingly, the brain concentrations of both GAA (Figure 3.6) and creatine (Figure 3.9) 
were not affected by the addition of either in the treatment diets. This might suggest that the 
brain has priority for the amino acids needed for creatine synthesis when arginine and 
methionine are limiting in the diet (Brosnan et al., 2009). Creatine is critical for the normal 
neurological function, as evidenced by the consequences of creatine deficiency symptoms 
(Leuzzi, 2002). However, it is unlikely that the piglet’s brain satisfies its creatine needs by de 
novo synthesis alone, because it expresses a very low activity of GAMT with no detectable 
levels of AGAT; hence, it is more likely that the brain depends on the periphery for a supply of 
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creatine (Brosnan et al., 2009; Dinesh et al., 2018).  While rat studies have suggested that the 
brain satisfies its own creatine supply (El‑Daher & Braissant, 2016), this seems unlikely for the 
piglet. Another possible reason for the lack of differences among our treatment groups in brain 
creatine concentration is that the turnover rate for brain creatine is very slow; therefore, we were 
unlikely to observe any differences in brain creatine concentration within one week of diet 
manipulation. Brosnan et al. (2009) found that neonatal piglets’ brain mass and creatine 
concentration did not change significantly over one week, between 4 and 11 days of age 
(Brosnan et al., 2009). Hence, it is not surprising that we did not measure any differences in 
creatine concentration within the duration of our experiment, which only lasted for one week.   
In the pancreas, supplementation of excess arginine and methionine appeared to enhance 
GAA retention (Figure 3.8). These data are in agreement with the pancreas AGAT activity data 
(Figure 3.5) which demonstrated an upregulation of AGAT in the adequate group, suggesting 
that more arginine was used for the synthesis of GAA in the pancreas. However, pancreas 
creatine concentrations (Figure 3.11) were not different regardless of treatment. Unlike the 
kidney, it appears that the pancreas is not affected by the provision of either creatine or GAA.  
 
4.3 Conclusion and future directions 
We hypothesized that a parenteral diet supplemented with creatine or its precursor GAA 
could spare arginine for growth and protein synthesis in neonatal piglets. We concluded that 
GAA supplementation with adequate methionine supports growth and nitrogen retention in the 
body. GAA may be a useful supplement in PN for neonates to satisfy creatine accretion and 
spare arginine, particularly because PN-fed neonates are at a high risk for arginine deficiency 
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(Becker et al., 2000); however, the requirement for methyl groups from methionine should be 
taken into account to avoid depletion of the methionine pool. 
One finding from this study that requires further investigation is the lack of difference in 
protein accretion rates between the piglets provided adequate arginine and methionine versus 
those fed diets known to be deficient.  This may be because the requirement for arginine is 
actually higher than that supplied in the adequate group (1.8 g.kg BW.-1day-1). 
GAA and creatine supplementation spared arginine, as evidenced by the arginine tracer 
kinetics; however, it was not clear that the spared arginine was diverted towards protein 
synthesis when assessed at the whole body level. It would also be of interest to assess whether 
creatine enhances the cognitive development of these piglets compared to no creatine 
supplementation.  It remains to be determined whether arginine was directed towards other 
important metabolic functions, or used to support organ-specific protein synthesis. A better 
method of assessing the protein status would be to measure the fractional protein synthesis rates 
of specific organs such as the liver, small intestine, and the skeletal muscle using a flooding dose 
of labeled phenylalanine. It would also be of interest to explore other metabolic pathways of 
arginine, such as the nitric oxide or polyamines pathways, to identify which pathways took 
priority when dietary arginine was limited but GAA or creatine was added to the diet.  
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Appendices 
Appendix I: The composition of the parenteral adaptation diet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  * modified from the work of Wykes et al. (1993) 
 
 
 
 
 
 
 
 
 
L-Amino Acid     g.L–1 g.kg BW–1.d–
1 
Alanine 4.50   1.22 
Arginine 3.68 1.00 
Aspartic acid 3.36 0.91 
Cysteine 0.80 0.22 
Glutamate 5.81 1.58 
Glycine 1.51 0.41 
Histidine 1.71 0.47 
Isoleucine 2.55 0.69 
Leucine 5.76 1.57 
Lysine 4.58 1.25 
Methionine 1.07 0.29 
Phenylalanine 3.03 0.82 
Proline 4.58 1.25 
Serine 5.33 1.45 
Taurine 0.25 0.07 
Tryptophan 1.17 0.32 
Tyrosine 0.43 0.12 
Valine 2.93 0.80 
Threonine 2.24 0.61 
D-glucose and major minerals 
Dextrose 90.30  
Trihydrate K2HPO4 1.57  
Monobasic KH2PO4  1.09  
K acetate  1.47  
NaCl  2.17  
MgSO4  0.78  
ZnSO4  0.09  
Calcium gluconate  6.41  
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Appendix II: The composition of the trace elements used in TPN diet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Element g/L 
Zinc, ZnSO4.7H2O 40.7 
Copper, CuSO4.5H2O 3.12 
Manganese, MnSO4.H2O 1.86 
Chromium, CrCl3.6H2O 0.0512 
Selenium, SeO2 0.0592 
Iodide, NaI 0.0220 
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Appendix III: The compositions of the multivitamin solutions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inactive ingredients in vial 1: 50 mg polysorbate 80, sodium hydroxide and/or 
hydrochloric acid for pH adjustment. 
Inactive ingredient in vial 2: 75 mg mannitol, citric acid and/or sodium citrate for 
pH adjustment 
 
 
 
 
Vitamin Unit/ 4 mL of vial 1 
Ascorbic acid (Vitamin C), mg 80 
Vitamin A (as palmitate), IU 2300 
Vitamin D3 (cholecalciferol), IU 400 
Thiamine (Vitamin B1) as hydrochloride, mg 1.2 
Riboflavin (Vitamin B2) as riboflavin-5-
phosphate sodium, mg 
1.4 
Pyridoxine HCl (Vitamin B6), mg 1 
Niacinamide, mg 17 
Dexpanthenol (as d-pantothenyl alcohol), mg 5 
Vitamin E (d1- α-tocopheryl acetate), IU 7 
Vitamin K1, mg 0.2 
 Unit/ 1 mL of vial 2 
Folic acid, mcg 140 
Biotin, mcg 20 
Vitamin B12 (cyanocobalamin), mcg 1 
